Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

SPC changes: August 2013

24 August 2013

Alfentanil

Alfentanil (alfentanil hydrochloride; Hameln) solution for injection 500µg/ml is now indicated for use in neonates, infants and children as an opioid in association with a hypnotic to induce anaesthesia and as a narcotic analgesic in association with general anaesthesia for both short and long surgical procedures. Extensive changes to the summary of product characteristics reflect this new indication.

Alimemazine

The summary of product characteristics for Alimemazine (alimemazine tartrate; Zentiva) has been updated to advise that the recommended dose must not be exceeded. Overdose can result in neuroleptic malignant syndrome, symptoms of which include a combination of hyperthermia, muscle rigidity, altered mental status and autonomic instability. Because the syndrome is potentially fatal, alimemazine must be immediately discontinued, and intensive clinical monitoring and symptomatic treatment must be initiated.

Gonapeptyl

Mood changes and depression have been added as common side effects to the summary of product characteristics for Gonapeptyl Depot (triptorelin acetate; Ferring).

Sytron

The dosage of Sytron (sodium feredetate; Archimedes) for the treatment of iron-deficiency anaemia in all paediatric age groups should be 3 to 6mg/kg per day (maximum 200mg) in two or three divided doses. For prophylaxis in babies and children, a daily dose of between 5mg and 60mg depending on the age of the child is required, according to the updated summary of product characteristics.

Torisel

Pneumocystis jiroveci pneumonia has been added as a rare adverse effect of treatment with Torisel (temsirolimus; Pfizer), now known as Torisel Injection 30mg. According to the updated summary of product characteristics, prophylaxis of Pneumocystis jiroveci pneumonia should be considered for patients who require concomitant use of corticosteroids or other immunosuppressive agents based upon current standard of care.

Tyverb

Tyverb (lapatinib; GlaxoSmithKline) is now indicated in combination with trastuzumab for adult patients with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy or therapies in combination with chemotherapy. There have been further changes to the summary of product characteristics because of this additional indication.

Velcade

Velcade in combination with dexamethasone, or with dexamethasone and thalidomide, is now indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. Further updates to the summary of product characteristics reflect this addition. Headache and hypocalcaemia have also been as common adverse reactions.

Zytiga

Myopathy and rhabdomyolosis have been added to the list of uncommon side effects of Zytiga (abiraterone acetate; Janssen) in the summary of product characteristics, and caution is now recommended in patients concomitantly treated with drugs known to be associated with myopathy or rhabdomyolysis. Diarrhoea has been added to the list of very common side effects. 

10 August 2013

Fuzeon

Autoimmune disorders such as Grave’s disease have been reported to occur in the setting of immune reactivation. These events can occur many months after initiation of treatment with Fuzeon (enfuvirtide; Roche), according to the updated summary of product characteristics.

Glivec

Glivec (imatinib; Novartis) is now licensed for use in paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia.

Jakavi

The summary of product characteristics for Jakavi (ruxolitinib; Novartis) now states that progressive multifocal leukoencephalopathy has been reported after treatment for myelofibrosis. Patients should be monitored and referral to a neurologist considered if symptoms occur and further dosing of Jakavi should be suspended until PML has been ruled out. 

Votrient

Serum liver tests are now recommended before starting treating with Votrient (pazopanib; GlaxoSmithKline) and at three weeks, five weeks, seven weeks and nine weeks afterwards, according to the summary of product characteristics.  

Xenical

Reports of renal failure and fatal cases of hepatitis have been added to the summary of product characteristics for Xenical (orlistat; Roche). Additionally, reduced efficacy of antidepressants or antipsychotics has been reported and Xenical should therefore be used with caution in these patients. 

 

 

 

 

Citation: The Pharmaceutical Journal URI: 20065403

Recommended from Pharmaceutical Press

  • Dale and Appelbe's Pharmacy and Medicines Law

    Dale and Appelbe's Pharmacy and Medicines Law

    This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.

    £57.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.